###begin article-title 0
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 66 70 <span type="species:ncbi:10116">Rats</span>
Amplified Hormonal Counterregulatory Responses to Hypoglycemia in Rats After Systemic Delivery of a SUR-1-Selective K+ Channel Opener?
###end article-title 0
###begin p 1
###xml 41 64 41 64 <email xmlns:xlink="http://www.w3.org/1999/xlink">rory.mccrimmon@yale.edu</email>
Corresponding author: Rory J. McCrimmon, rory.mccrimmon@yale.edu
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
###xml 54 55 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 67 70 67 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 232 235 232 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
OBJECTIVE- In glucose-sensing neurons, ATP-sensitive K+ channels (KATP channels) are thought to translate metabolic signals into an alteration in neuronal firing rates. Because these neurons express the Kir6.2/SUR-1 isoform of the KATP channel, we sought to examine the therapeutic potential of the SUR-1-selective potassium channel opener (KCO), NN414, to amplify counterregulatory response to hypoglycemia.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 104 123 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
###xml 329 333 <span type="species:ncbi:10116">rats</span>
RESEARCH DESIGN AND METHODS- In vivo dose-response studies with NN414 delivered intravenously to normal Sprague-Dawley rats before the induction of controlled hypoglycemia were performed. Based on these studies, the potential for NN414 to restore counterregulatory responses in chronically cannulated nondiabetic and diabetic BB rats was explored using the in vivo hyperinsulinemic-hypoglycemic clamp technique.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 435 439 <span type="species:ncbi:10116">rats</span>
RESULTS- NN414 delivered systemically amplified epinephrine responses during acute hypoglycemia and showed a persisting effect to amplify the epinephrine response when given 24 h before the hypoglycemic study. Local delivery of a potassium-channel blocker to the ventromedial hypothalamus reversed the effects of systemic NN414. In addition, NN414 amplified the epinephrine response to hypoglycemia in both nondiabetic and diabetic BB rats with defective hormonal counterregulation.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
###xml 221 226 <span type="species:ncbi:9606">human</span>
CONCLUSIONS- These studies demonstrate in a variety of rodent models that systemic delivery of Kir6.2/SUR-1-selective KCOs enhance the glucose counterregulatory response to insulin-induced hypoglycemia. Future studies in human subjects are now required to determine their potential as a therapy for hypoglycemia-associated autonomic failure in type 1 diabetes.
###end p 6
###begin p 7
Published ahead of print at  on 5 September 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 336 337 336 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 686 687 683 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 777 778 774 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 1001 1002 998 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 1049 1050 1046 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 1063 1064 1060 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 1286 1287 1283 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 1288 1289 1285 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 1308 1310 1305 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 903 911 <span type="species:ncbi:9606">patients</span>
###xml 1056 1061 <span type="species:ncbi:9606">human</span>
###xml 1197 1202 <span type="species:ncbi:9606">human</span>
The benefits of lowering average blood glucose levels in type 1 diabetes to reduce the risk of long-term microvascular complications are well established. In clinical practice, the degree to which this can be achieved is often limited by the increased risk of severe hypoglycemia that accompanies intensified glucose-lowering regimens (1,2). Individuals with type 1 diabetes are, moreover, particularly prone to develop hypoglycemia because of defects in the normal compensatory homeostatic defense response. Almost all individuals with type 1 diabetes fail to release glucagon in response to hypoglycemia, a defect that appears to relate to the progressive loss of beta-cell function (3) and is thought to arise predominantly through the loss of intraislet insulin signaling (4). This leaves epinephrine as the major hormonal counterregulatory defense against low blood glucose. However, a majority of patients will also develop additional deficiencies in the epinephrine counterregulatory response (5). It has now been established in both rodent (6) and human (7) studies that antecedent exposure to hypoglycemia is a major factor involved in the genesis of this defect. Several small trials in human subjects have shown that strict avoidance of hypoglycemia can improve epinephrine (8,9) and symptomatic (10) responses during a subsequent hypoglycemic clamp study. The difficulty in achieving strict hypoglycemia avoidance in both of these trials means that this intervention has not become part of routine clinical practice. Thus, therapeutic options designed to limit the impact of hypoglycemia during intensive insulin therapy remain limited.
###end p 9
###begin p 10
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 705 706 702 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 717 720 714 717 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 752 754 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 755 757 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
The stimulus to epinephrine release during hypoglycemia is thought to result from activation of specialized glucose-sensing neurons within the brain (11-14) and periphery (15). Glucose-sensing neurons use glucose as a signaling molecule to alter their firing rate and are of two predominant subtypes, namely, glucose-excited neurons, whose firing rate increases, and glucose-inhibited neurons, whose firing rate decreases, as ambient glucose levels rise (16-18). Based largely on data in rodents, it is currently believed that glucose-sensing neurons react to alterations in extracellular glucose using mechanisms similar to those used by the pancreatic beta-cell, with glucokinase and the ATP-sensitive K+ channel (KATP) as key steps in this process (19,20).
###end p 10
###begin p 11
###xml 1 4 1 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 116 119 116 119 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 232 233 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 295 298 295 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 370 373 367 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 447 449 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 450 452 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 477 480 474 477 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 650 652 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 653 655 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 659 662 653 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 791 793 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 794 796 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 920 922 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 962 964 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 965 967 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 968 970 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 1008 1010 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 1284 1286 1278 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 1361 1364 1355 1358 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 1497 1499 1491 1493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 1511 1514 1505 1508 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 1646 1648 1640 1642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 1772 1774 1766 1768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 1894 1896 1888 1890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 957 960 <span type="species:ncbi:10116">rat</span>
###xml 976 981 <span type="species:ncbi:10090">mouse</span>
###xml 1238 1242 <span type="species:ncbi:10090">mice</span>
###xml 1640 1644 <span type="species:ncbi:10116">rats</span>
KATP channels provide a link between neuronal metabolism and membrane potential in many tissues (21,22). Classical KATP channels comprise two subunits: a receptor (SUR-1, SUR-2A, or SUR-2B) of sulfonylureas and an inward-rectifier K+ channel member, Kir6.2 (22,23). Skeletal muscle and cardiac KATP channels comprise SUR-2A and Kir6.2, whereas the pancreatic beta-cell KATP channel, the prototype glucose-sensing cell, comprises SUR-1 and Kir6.2 (21-24). In the pancreas, the KATP channel has been shown to play a key role in the mechanism by which beta-cells regulate insulin release in response to changes in the glucose to which they are exposed (25,26). KATP channels have been demonstrated throughout the brain, including hypothalamic regions thought to be involved in glucose sensing (27-29). Examination of gene expression in glucose-sensing neurons using single-cell RT-PCR identified mRNA for SUR-1 and Kir6.2 (30). Electrophysiological studies of rat (20,31,32) and mouse brain slice preparations (33) have demonstrated that sulfonylureas can stimulate the firing of glucose-excited neurons and can alter the response of glucose-excited neurons to changes in ambient glucose levels. In animal models, transgenic Kir6.2 knockout mice show impaired glucose counterregulation (33), and we have recently shown in vivo that pharmacological closure of the KATP channel in the ventromedial hypothalamus (VMH; a key glucose-sensing region) via direct microinjection of glibenclamide suppressed (34), whereas KATP channel openers (KCOs) amplified, the counterregulatory response to hypoglycemia in both normal and recurrently hypoglycemic rats (35). In this later study, the SUR-1-selective KCO NN414, when microinjected into the VMH, a key brain glucose-sensing region (36), amplified hypoglycemic counterregulation at significantly lower concentrations than the nonselective KCO, diazoxide (35).
###end p 11
###begin p 12
###xml 41 44 41 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 529 533 <span type="species:ncbi:10116">rats</span>
Taken together, these data suggest that KATP channels allow glucose-sensing neurons to translate the metabolic signal into an alteration in neuronal firing rates and, moreover, that KCOs may offer a potential therapeutic option for individuals with type 1 diabetes. In the current study, this hypothesis is explored in a series of rodent models. Our data show that systemic administration of a SUR-1-selective KCO has a consistent effect to amplify the epinephrine response to controlled hypoglycemia in nondiabetic and diabetic rats and in those with defective counterregulation.
###end p 12
###begin title 13
RESEARCH DESIGN AND METHODS
###end title 13
###begin p 14
###xml 21 22 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 87 88 83 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 375 379 371 375 <sc xmlns:xlink="http://www.w3.org/1999/xlink">a.m.</sc>
###xml 81 85 <span type="species:ncbi:10116">rats</span>
###xml 278 282 <span type="species:ncbi:10116">rats</span>
Male Sprague-Dawley (n = 102; weight 305 +/- 4 g [means +/- SE]) and diabetic BB rats (n = 12; disease duration 2-4 weeks) were housed in the Yale Animal Resource Center, fed a standard pellet diet (Agway Prolab 3000), and maintained on a 12-h/12-h day/night cycle. Diabetic BB rats were maintained on once-daily protamine zinc insulin, with doses based on body weight, 9:00 a.m. glucose, and protocol. The animal care and experimental protocols were reviewed and approved by the Yale Institutional Animal Care and Use Committee.
###end p 14
###begin title 15
Surgery.
###end title 15
###begin p 16
###xml 645 647 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
One week before each study, all animals were anesthetized with an intraperitoneal injection (1 ml/kg) of a mixture of xylazine (20 mg/ml AnaSed; Lloyd Laboratories, Shenandoah, IA) and ketamine (100 mg/ml Ketaset; Aveco, Fort Dodge, IA) in a ratio of 1:2 (vol:vol), before undergoing vascular surgery for the implantation of vascular catheters in a carotid artery and jugular vein. In some rodents, after this procedure, microinjection guide cannulas were bilaterally inserted into the VMH (coordinates from bregma: antero-posterior -2.6 mm, medio-lateral +/-3.8 mm, and dorso-ventral -8.3 mm at an angle of 20degrees), as described previously (34).
###end p 16
###begin title 17
Recurrent hypoglycemia protocol.
###end title 17
###begin p 18
###xml 709 711 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 18 22 <span type="species:ncbi:10116">rats</span>
###xml 64 69 <span type="species:ncbi:9606">human</span>
###xml 346 350 <span type="species:ncbi:10116">rats</span>
###xml 429 433 <span type="species:ncbi:10116">rats</span>
In these studies, rats received an intraperitoneal injection of human regular insulin (Eli Lilly, Indianapolis, IN) at a dose of 10 units/kg given once daily for the 3 consecutive days before the glucose clamp study. Each episode of hypoglycemia (tail vein blood glucose 1.7-2.2 mmol/l [30-40 mg/dl]) lasted for approximately3 h, after which the rats were given free access to food and intraperitoneal dextrose, if required. Any rats experiencing a seizure were excluded and did not undergo a subsequent clamp study. The model of recurrent hypoglycemia used in our laboratory has been previously reported in detail and has been shown to induce suppression of epinephrine responses to subsequent hypoglycemia (37).
###end p 18
###begin title 19
KCOs.
###end title 19
###begin p 20
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 141 143 141 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
This study used intravenous delivery of the SUR-1-selective KCO NN414 (Novo Nordisk A/S, Malvo, Denmark) (38). NN414 was prepared in 1.5 mg m-1 artificial extracellular fluid (aECF) for systemic delivery. In all studies, NN414 was delivered systemically 30 min before the induction of hypoglycemia.
###end p 20
###begin title 21
Microinjection.
###end title 21
###begin p 22
###xml 419 421 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 189 193 <span type="species:ncbi:10116">Rats</span>
###xml 561 565 <span type="species:ncbi:10116">rats</span>
###xml 619 623 <span type="species:ncbi:10116">rats</span>
On the morning of the study, 26-gauge microinjection needles, designed to extend 1 mm beyond the tip of the guide cannula (Plastics One, Roanoke, VA), were inserted bilaterally to the VMH. Rats were then microinjected over 2.5 min (0.1 mul/min) with either glibenclamide (12.4 ng dissolved in aECF and 0.5% DMSO or control [aECF with 0.5% DMSO]) using a CMA-102 infusion pump (CMA Microdialysis, North Chelmsford, MA) (34). Microinjection occurred immediately before the hyperinsulinemic-hypoglycemic clamp study as detailed below. At the end of the study, the rats were killed, and probe position was confirmed in all rats.
###end p 22
###begin title 23
Infusion protocol.
###end title 23
###begin p 24
###xml 280 281 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 339 341 339 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 347 349 347 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 110 114 <span type="species:ncbi:10116">rats</span>
###xml 275 278 <span type="species:ncbi:10116">rat</span>
###xml 362 367 <span type="species:ncbi:9606">human</span>
In all experiments, the same hyperinsulinemic-hypoglycemic clamp infusion protocol was used. Overnight-fasted rats had their vascular catheters opened and were then allowed to settle over 90 min. Thereafter, a hyperinsulinemic-hypoglycemic clamp technique as adapted for the rat (6) was initiated. Briefly, at time = 0, a 90-min 20 mU . kg-1 . min-1 infusion of human regular insulin (Eli Lilly) was started, and the plasma glucose was allowed to fall to 50 mg/dl (approximately2.8 mmol/l), where it was maintained for 90 min using a variable rate 20% dextrose infusion (based on frequent [-5 min] plasma glucose determinations). Samples for measurement of the hormones epinephrine, norepinephrine, glucagon, insulin, and C-peptide were taken at -30, 0, 60, and 90 min.
###end p 24
###begin title 25
Analytical procedures.
###end title 25
###begin p 26
###xml 389 390 387 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Plasma glucose was measured by the glucose oxidase method (Beckman, Fullerton, CA). Catecholamine analysis was performed by high-performance liquid chromatography using electrochemical detection (ESA, Acton, MA); plasma insulin and glucagon were measured by radioimmunoassay (Linco, St. Charles, MO). All data are expressed as the means +/- SE and were compared using Student's two-tailed t test. (Prism 4.0; GraphPad Software, San Diego, CA).
###end p 26
###begin title 27
RESULTS
###end title 27
###begin title 28
SUR-1 KCO delivery amplifies the epinephrine response to hypoglycemia in a dose-dependent manner.
###end title 28
###begin p 29
###xml 170 171 170 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 258 259 258 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 360 361 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 397 398 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 427 428 427 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 494 501 494 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 675 676 671 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 17 21 <span type="species:ncbi:10116">rats</span>
###xml 179 183 <span type="species:ncbi:10116">rats</span>
###xml 802 806 <span type="species:ncbi:10116">rats</span>
Overnight-fasted rats were given intravenous bolus injections of NN414 in doses of 6, 0.6, and 0.06 mg/kg or vehicle 30 min before performing a hypoglycemic clamp study (n = 6-10 rats in each group). Additional studies were performed with 0.006 mg/kg NN414 (n = 4), but these data did not differ significantly from the control studies (data not shown). Basal (t = -30 min), after NN414 injection (t = 0 min), and hypoglycemia (t = 90 min) levels of glucose, C-peptide, and insulin are shown in Table 1. Of note, only the higher dose of NN414 (6 mg/kg) induced a significant fall in C-peptide before initiation of the hypoglycemic clamp study (308 +/- 53 to 75 +/- 16 pmol/l; P < 0.05). In addition, mean plasma glucose achieved during the clamp procedure was slightly but significantly higher in those rats that had been given 0.6 and 0.06 mg/kg NN414.
###end p 29
###begin p 30
###xml 415 416 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 409 416 409 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 523 524 523 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 517 524 517 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 687 688 675 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 681 688 669 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 1027 1028 1015 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1021 1028 1009 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>D</italic></xref>
###xml 773 777 <span type="species:ncbi:10116">rats</span>
During the basal period, mean counterregulatory hormone levels did not differ between groups and were not affected by injection of NN414 or control (data not shown). Hypoglycemia induced significant rises in all counterregulatory hormones in both control and NN414 groups, with the exception of high-dose NN414, in which glucagon failed to rise during hypoglycemia, despite the marked reduction in C-peptide (Fig. 1A). In contrast, NN414 had a marked and significant effect on plasma epinephrine during hypoglycemia (Fig. 1B). NN414 given at 0.6 mg/kg produced an approximately108% increase in the peak plasma epinephrine over the control group. The rise in plasma norepinephrine (Fig. 1C) was substantially less than the rise in epinephrine, and peak levels were lower in rats treated with 0.6 and 6 mg/kg NN414. However, the overall glucose counterregulatory response was significantly amplified with NN414, with all doses resulting in a clear reduction in the amount of exogenous glucose (glucose infusion rate [GIR]; Fig. 1D) required to maintain the hypoglycemic clamp. After 0.6 mg/kg NN414, this represented an approximately80% reduction in the GIR.
###end p 30
###begin p 31
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 331 332 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 461 462 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 619 621 601 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 627 629 609 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 631 632 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 724 725 702 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 124 143 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
###xml 514 518 <span type="species:ncbi:10116">rats</span>
To explore the utility of the nonselective KCO diazoxide, an identical hyperinsulinemic hypoglycemia study was performed in Sprague-Dawley rats. Diazoxide (6 mg/kg; n = 6) delivered systemically significantly amplified the mean (+/- SE) peak epinephrine (2,307 +/- 342 vs. 1,479 +/- 205 pg/ml, diazoxide vs. control, respectively; P < 0.05) but not the peak norepinephrine (507 +/- 89 vs. 539 +/- 29 pg/ml; NS) or peak glucagon (354 +/- 38 vs. 252 +/- 82 ng/l; P = 0.2) response to hypoglycemia. Diazoxide-treated rats also required less glucose during the hypoglycemic clamp study (4.9 +/- 1.6 vs. 10.5 +/- 1.8 mg . kg-1 . min-1; P < 0.05). C-peptide levels fell after diazoxide injection (476 +/- 64 to 313 +/- 43 pmol/l; P < 0.05) and during the hypoglycemic clamp study (34 +/- 6 pmol/l).
###end p 31
###begin title 32
Antecedent delivery of SUR-1 KCO amplifies epinephrine response to subsequent hypoglycemia.
###end title 32
###begin p 33
###xml 226 227 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 245 246 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 836 839 798 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;D</italic>
###xml 830 839 792 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A&#8211;D</italic></xref>
###xml 145 164 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
###xml 307 311 <span type="species:ncbi:10116">rats</span>
To determine whether the SUR-1 KCO NN414 would have a persisting effect on counterregulatory responses to hypoglycemia, chronically catheterized Sprague-Dawley rats were injected once daily intravenously with 0.6 mg/kg NN414 (n = 7) or vehicle (n = 7) for 3 consecutive days. On day 4, the overnight-fasted rats underwent a hypoglycemic clamp study. Mean (+/- SE) plasma glucose (47 +/- 3 vs. 44 +/- 3 mg/dl; NS), insulin (4,347 +/- 723 vs. 4,876 +/- 642 pmol/l; NS) and C-peptide (39 +/- 3 vs. 52 +/- 11 pmol/l; NS) during hypoglycemia did not differ between antecedent control or NN414-injected groups, respectively. However, during hypoglycemia, antecedent NN414 resulted in an approximately54% increase in the peak epinephrine response and an approximately71% reduction in the GIR required to maintain the hypoglycemic clamp (Fig. 2A-D).
###end p 33
###begin title 34
###xml 5 8 5 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
VMH KATP channel blockade reverses the action of systemic SUR-1 KCO.
###end title 34
###begin p 35
###xml 392 395 392 395 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 449 450 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 488 489 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 689 692 688 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;C</italic>
###xml 683 692 682 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A&#8211;C</italic></xref>
###xml 972 975 971 974 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 999 1002 998 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;C</italic>
###xml 993 1002 992 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A&#8211;C</italic></xref>
###xml 1170 1171 1165 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1267 1269 1258 1260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1275 1277 1266 1268 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1293 1294 1284 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 145 149 <span type="species:ncbi:10116">rats</span>
###xml 335 339 <span type="species:ncbi:10116">rats</span>
To determine whether the systemic effects of the KCO NN414 were potentially mediated through an action on the VMH, a key glucose-sensing region, rats were systemically administered with 0.6 mg/kg NN414 30 min before performing a hyperinsulinemic-hypoglycemic clamp study as above. In addition, 5 min before the start of the clamp, the rats were bilaterally microinjected to the VMH with the KATP channel blocker, glibenclamide (12.4 ng in 0.25 mul; n = 10), or control solution (vehicle; n = 11). Mean plasma glucose, insulin, and C-peptide did not differ between groups under basal or hypoglycemic conditions (data not shown) nor did basal levels of the counterregulatory hormones (Fig. 3A-C). In control studies, systemic NN414 combined with VMH-vehicle microinjection produced a similar stimulus to epinephrine and glucagon as that seen in the dose-response studies. This effect was significantly blunted when systemic NN414 (KCO) was combined with VMH-glibenclamide (KATP channel closer) (Fig. 3A-C). VMH-glibenclamide resulted in a 52% reduction in peak plasma epinephrine (4,287 +/- 807 vs. 2,074 +/- 316 pg/medio-lateral; control vs. glibenclamide, respectively; P < 0.05) and a 90% increase in mean GIR during hypoglycemia (4.2 +/- 1.0 vs. 8.0 +/- 1.2 mg . kg-1 . min-1, respectively; P < 0.05). As in the previous studies, no effect was seen on peak glucagon (290 +/- 48 vs. 321 +/- 51 ng/l; NS) or norepinephrine (546 +/- 55 vs. 573 +/- 122 pg/ml; NS).
###end p 35
###begin title 36
###xml 110 114 <span type="species:ncbi:10116">rats</span>
Systemic SUR-1 KCO delivery amplifies the epinephrine response to hypoglycemia in nondiabetic and diabetic BB rats exposed to prior hypoglycemia.
###end title 36
###begin p 37
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 1037 1038 1029 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1031 1038 1023 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 1166 1167 1146 1147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1160 1167 1140 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 1169 1170 1149 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1324 1325 1304 1305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1318 1325 1298 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>D</italic></xref>
###xml 1327 1328 1307 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 522 526 <span type="species:ncbi:10116">rats</span>
To determine whether NN414, given systemically, would improve the counterregulatory responses to hypoglycemia in a rodent model of hypoglycemia-associated autonomic failure (HAAF), hyperinsulinemic-hypoglycemic clamp studies were performed in nondiabetic rodents who had been exposed to three consecutive, once-daily episodes of 10 mU/kg insulin-induced hypoglycemia. We have previously reported that this model induces defective counterregulatory responses to subsequent hypoglycemia (35,37). As in the previous studies, rats received 0.6 mg/kg NN414 or vehicle delivered intravenously 30 min before the clamp procedure. Basal levels of glucose, insulin, and counterregulatory hormones did not differ between groups nor did levels of glucose and insulin during the clamp procedure. Plasma C-peptide fell in both groups from baseline values of 218 +/- 45 and 264 +/- 39 to 34 +/- 6 and 28 +/- 4 pmol/l (control vs. NN414, respectively; NS). Consistent with the earlier studies, no effect of NN414 was seen on peak plasma glucagon (Fig. 4A), whereas the peak epinephrine response during the subsequent hypoglycemic challenge was increased by approximately114% (Fig. 4B; P < 0.05). The increased glucose counterregulatory response was reflected in a 70% reduction in the GIR required to maintain the hypoglycemic clamp (Fig. 4D; P < 0.01).
###end p 37
###begin p 38
###xml 487 489 483 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 594 595 586 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 612 613 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 846 847 838 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 840 847 832 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 989 990 969 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 983 990 963 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 992 993 972 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1194 1195 1174 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1188 1195 1168 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 1197 1198 1177 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1274 1275 1242 1243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1268 1275 1236 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 1277 1278 1245 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 70 74 <span type="species:ncbi:10116">rats</span>
###xml 127 131 <span type="species:ncbi:10116">rats</span>
###xml 654 658 <span type="species:ncbi:10116">rats</span>
###xml 881 885 <span type="species:ncbi:10116">rats</span>
###xml 1090 1094 <span type="species:ncbi:10116">rats</span>
Subsequently, we examined the effect of systemic NN414 in diabetic BB rats, a rodent model of type 1 diabetes. The diabetic BB rats were also subjected to 3-day antecedent hypoglycemia to induce further defects in the counterregulatory response. Basal levels of glucose, insulin, and counterregulatory hormones did not differ between groups nor did levels of glucose and insulin during the clamp procedure. As expected, plasma C-peptide was low under basal (42 +/- 10 and 36 +/- 3 pmol l-1) and hypoglycemic (36 +/- 1 and 29 +/- 3 pmol/l) conditions and did not differ between groups (control [n = 6] vs. NN414 [n = 6], respectively). In the diabetic BB rats, no significant rise in plasma glucagon from baseline was seen during hypoglycemia in either group, and peak plasma glucagon during hypoglycemia also did not differ between groups (Fig. 5A). However, as in the nondiabetic rats, systemic NN414 produced a marked stimulus to epinephrine secretion (approximately200% increase; Fig. 5B; P < 0.05), although absolute epinephrine levels remained lower than those seen in the nondiabetic rats. In addition, NN414 significantly amplified the norepinephrine response during hypoglycemia (Fig. 5C; P < 0.05), the overall effect being to reduce GIR by approximately60% (Fig. 5D; P < 0.01).
###end p 38
###begin title 39
DISCUSSION
###end title 39
###begin p 40
###xml 198 202 <span type="species:ncbi:10116">rats</span>
###xml 222 226 <span type="species:ncbi:10116">rats</span>
###xml 546 549 <span type="species:ncbi:10116">rat</span>
###xml 660 666 <span type="species:ncbi:9606">humans</span>
In the present study, systemically delivered SUR-1-selective KCO was shown to amplify the glucose counterregulatory response to acute hypoglycemia in normal and recurrently hypoglycemic nondiabetic rats and in diabetic BB rats exposed to recurrent hypoglycemia (a rodent model of type 1 diabetes with markedly impaired glucose counterregulation). Moreover, the SUR-1-selective KCO was effective when given acutely or when delivered for 3 consecutive days before the hyperinsulinemic-hypoglycemic clamp study. Taken together, these studies in the rat suggest that SUR-1-selective KCOs may have therapeutic potential for the treatment of HAAF in type 1 diabetic humans.
###end p 40
###begin p 41
###xml 5 8 5 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 790 792 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 854 857 854 857 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 1255 1257 1255 1257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 1339 1341 1339 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
The KATP channel consists of pore-forming Kir6.x subunits that associate with different types of regulatory sulfonylurea receptor subunits: SUR-1, SUR-2A, and SUR-2B. SUR-2 channels are predominantly expressed in cardiac/skeletal muscle (SUR-2A) and vascular smooth muscle (SUR-2B) (39), activation of which can cause vasodilation and effect cardiac muscle contractility. Diazoxide activates both SUR-1 and SUR-2B regulatory subunits. When delivered directly to the VMH, diazoxide can amplify the counterregulatory response to hypoglycemia (35), and in the current study, when given systemically at a dose of 6 mg/kg, diazoxide can also amplify the counterregulatory response (the higher dose required consistent with the reduced potency of diazoxide to activate SUR-1 compared with NN414 [38]). However, through its action on the SUR-2B subunit of the KATP channel, the use of diazoxide is limited by its potential to cause vasodilation, reflex tachycardia, and hirsuitism (also thought to be SUR2 mediated). The current studies used a compound, NN414, developed by Novo Nordisk, as a selective SUR-1 KCO. In vitro studies have shown that NN414 is highly selective for the Kir6.2/SUR-1 channel, with no significant activation of SUR-2A and -2B channels (38). NN414, even at high doses, has been shown to have no effect on blood pressure (40). Thus, for an effective long-term therapy for individuals with type 1 diabetes, a SUR-1-selective agent is liable to be both more effective in its action on glucose sensing and less likely to be associated with these adverse effects.
###end p 41
###begin p 42
###xml 52 54 52 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 178 184 <span type="species:ncbi:9606">humans</span>
###xml 532 538 <span type="species:ncbi:9606">humans</span>
Our findings contrast with those of Raju and Cryer (41), who examined the effect of oral diazoxide (6 mg/kg) on the counterregulatory responses to hypoglycemia in 14 nondiabetic humans. Diazoxide, given orally, suppressed basal C-peptide and suppressed the glucagon response to hypoglycemia induced 2 h later while having no effect on epinephrine, norepinephrine, or neurogenic symptoms (41). Similarly, Bingham et al. (42) reported no effect of oral diazoxide (5 mg/kg) on the hormonal counterregulatory response in 10 nondiabetic humans. In our rodent study, diazoxide given intravenously 30 min before hypoglycemia also suppressed C-peptide but resulted in an amplified epinephrine response during hypoglycemia. The glucagon response was also increased but not significantly so. These differences may reflect species differences in Kir6.2/SUR-1 channel expression and function, and in addition, the higher systemic diazoxide levels that were probably achieved in the rodent may have induced a degree of hypotension (not measured in the present study) that may have contributed to the epinephrine response. However, this would not explain the NN414 findings. Furthermore, in pilot studies we found that oral NN414 (1.2 mg/kg) has the same effect to amplify counterregulation during hypoglycemia (data not shown). The consistent effect of NN414 to amplify the epinephrine counterregulatory response suggests that higher systemic levels of diazoxide may be necessary to induce a SUR-1-mediated action on the catecholaminergic response to hypoglycemia.
###end p 42
###begin p 43
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 506 509 506 509 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 602 605 594 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 803 805 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 606 610 <span type="species:ncbi:10090">mice</span>
###xml 630 634 <span type="species:ncbi:10090">mice</span>
It was notable in the present study that high-dose NN414 markedly suppressed glucagon secretion during hypoglycemia. Before induction of the hypoglycemic clamp, plasma C-peptide was also more markedly suppressed by high-dose NN414. This latter finding is consistent with the intraislet insulin hypothesis, in which defective glucagon secretion during hypoglycemia is thought to arise through a failure of intraislet insulin levels to fall (41). Alternatively, it may represent a direct action of NN414 on KATP channels in the pancreatic alpha-cells. It has been shown in alpha-cells isolated from SUR-1-/- mice, but not wild-type mice, that both tolbutamide and glucose fail to produce membrane depolarization and that diazoxide reduces glucagon secretion to the same extent as an elevation of glucose (43). This effect might arise from the distinct electrophysiological properties of alpha-cells.
###end p 43
###begin p 44
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 687 691 <span type="species:ncbi:10116">rats</span>
###xml 712 716 <span type="species:ncbi:10116">rats</span>
It was also notable that norepinephrine responses during hypoglycemia did not parallel those of epinephrine. During hypoglycemia, systemic norepinephrine has not proven discriminatory in previous clamp studies in rodents by our group (34,35). Norepinephrine is released primarily from sympathetic nerve terminals, and so, systemic levels provide only a weak index of local sympathetic neural activity. Plasma norepinephrine is also both lower than epinephrine (approximately10-25%) and a less potent agonist of adrenergic receptors, so small differences between groups in systemic levels are not informative. It was also of note that the absolute effect of NN414 was less in diabetic BB rats than in nondiabetic rats. This suggests that additional mechanisms, not reversible through KCO therapy, may contribute to defective counterregulation in diabetes.
###end p 44
###begin p 45
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r45">45</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 546 549 546 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 730 733 730 733 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 800 803 800 803 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 1176 1178 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 1627 1629 1627 1629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 1930 1932 1930 1932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r49">49</xref>
###xml 2044 2046 2044 2046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r50">50</xref>
###xml 2296 2298 2296 2298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r51">51</xref>
###xml 2327 2330 2327 2330 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 1352 1355 <span type="species:ncbi:40279?0.0430622009569378|species:ncbi:12181?0.019138755980861243|species:ncbi:33763?0.014354066985645933">PMV</span>
###xml 1374 1377 <span type="species:ncbi:40279?0.0430622009569378|species:ncbi:12181?0.019138755980861243|species:ncbi:33763?0.014354066985645933">PMV</span>
###xml 1481 1484 <span type="species:ncbi:40279?0.0430622009569378|species:ncbi:12181?0.019138755980861243|species:ncbi:33763?0.014354066985645933">PMV</span>
###xml 1766 1770 <span type="species:ncbi:9615">dogs</span>
###xml 2170 2175 <span type="species:ncbi:9606">human</span>
It is interesting to speculate on where the systemically delivered KCO might act. Although the Kir6.x pore-forming unit is widely expressed in the body, the expression of SUR-1 is predominantly limited to brain and pancreas (44). Within the brain, SUR-1 and Kir6.x are expressed both in regions known to be involved in glucose sensing and in other brain regions (45). Glucose-sensing neurons in the VMH are known to express SUR-1 (30). Our data demonstrating that the action of systemic NN414 could be reversed after the direct application of a KATP channel blocker to the VMH suggest this is one potential site that mediates the effect of NN414. That being said, it is also possible that the changes seen were the net result of KATP channel opening at a different site and an independent action of KATP channel closure in the VMH. NN414, if acting centrally, could equally be acting on glucose-sensing neurons in other brain regions such as the hindbrain. Sulfonylurea-like compounds are not generally thought to cross the blood-brain barrier (46), although recent studies of KCOs in ischemic preconditioning in the brain provide some evidence that they might act centrally (47). Unfortunately, a radiolabeled form of NN414 is not available to directly test this question. Another possibility is that NN414 is interacting with portal-mesenteric vein (PMV) glucose sensors. PMV glucose sensors play a role in the modulation of counterregulatory responses to hypoglycemia. However, PMV glucose sensors are thought to play a greater role in slow-fall rather than the rapid induction of hypoglycemia induced in the present study (48), and a role for SUR-1 in these sensors has not been established. Another peripheral glucose sensor is located in the carotid body, but dogs with carotid body resections showed blunted glucagon and cortisol secretion during hypoglycemia, with epinephrine and norepinephrine release being unaffected (49). Finally, SUR-1 and Kir6.2 are coexpressed with glucagon-like peptide 1 (GLP-1) in intestinal L- and K-cells (50), which raises the possibility of an indirect action through altered GLP-1 secretion. However, we have previously shown in human subjects that glucose ingestion while hypoglycemia is maintained leads to an amplification of the epinephrine response (51), which would suggest that KATP closure, rather than opening, within L-cells mediates this effect. Moreover, GLP-1 secretion is liable to be minimal during hypoglycemia.
###end p 45
###begin p 46
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 565 570 <span type="species:ncbi:9606">human</span>
One other notable finding in the present study was that 3 days of NN414 given as a single intravenous bolus resulted in an amplified epinephrine response to a subsequent controlled hypoglycemic challenge. The ability of a compound to amplify counterregulatory responses to a subsequent episode of hypoglycemia and not just when given during the hypoglycemic episode would be important for type 1 diabetic individuals in whom hypoglycemia does usually occur at predictable times. Why this effect should occur after 3 days of NN414 therapy is unknown. NN414 given to human subjects at a similar dose (0.625 mg/kg) has a half-life of only 1.2 h (40), and so it seems unlikely to represent a persisting direct action on the Kir6.2/SUR-1 channel. This finding therefore raises the possibility that NN414 could through secondary effects render the glucose-sensing pathway more sensitive to a subsequent hypoglycemic challenge.
###end p 46
###begin p 47
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 412 417 <span type="species:ncbi:9606">human</span>
###xml 515 520 <span type="species:ncbi:9606">human</span>
###xml 706 711 <span type="species:ncbi:9606">human</span>
In summary, in the current study, we have been able to demonstrate in a variety of rodent models that the SUR-1/Kir6.2-selective KCO when given systemically is able to amplify epinephrine responses to hypoglycemia. These studies provide the first evidence of a potential therapeutic intervention for HAAF in type 1 diabetes. The dose of NN414 that we used in these rodent studies compares with that of trials in human subjects assessing pharmacokinetics after single-dose NN414 (0.625-12.5 mg/kg) (40); however, no human studies using this compound during hypoglycemia have as yet been performed. Future studies in rodent models designed to establish the best strategies for delivering these agents and in human subjects to validate the rodent data are now required.
###end p 47
###begin p 48
R.J.M. has received a Career Development Award from the Juvenile Diabetes Research Foundation. This work has received grants from the National Institutes of Health (DK-069831 and DK-20495) and the Yale Juvenile Diabetes Research Foundation Center for the Study of Hypoglycemia.
###end p 48
###begin p 49
We thank Aida Groszmann, Andrea Belous, and Ralph Jacob for their invaluable technical assistance. We also thank John Bondo Hansen for comments on the manuscript and Novo Nordisk for providing the NN414 used in these studies.
###end p 49
###begin title 50
REFERENCES
###end title 50
###begin p 51
###xml 161 162 161 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 341 341 315 315 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cjs2117.jpg"/>
###xml 361 361 335 335 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cjs2106.jpg"/>
###xml 383 383 357 357 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cjs2099.jpg"/>
###xml 395 396 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Systemic delivery of the SUR-1-selective KCO NN414 amplifies the glucose counterregulatory response to acute hypoglycemia in nondiabetic rodents. Peak glucagon (A), peak epinephrine (B), peak norepinephrine (C), and GIRs (D) required to maintain the hypoglycemic clamp are shown for control (blacksquare, square, filled), 0.06 mg/kg NN414 ( ), 0.6 mg/kg NN414 (), and 6 mg/kg NN414 () studies. *P < 0.05 vs. control.
###end p 51
###begin p 52
###xml 120 121 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 141 142 141 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 178 179 178 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 318 320 313 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 396 397 363 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 221 225 <span type="species:ncbi:10116">rats</span>
Antecedent delivery of SUR-1 KCO amplifies epinephrine response to subsequent hypoglycemia. Graphs show plasma glucose (A), plasma glucagon (B), plasma epinephrine (C), and GIR (D) during hyperinsulinemic hypoglycemia in rats injected once daily on 3 prior consecutive days with either control (o, square) or 0.6 mg kg-1 NN414 (*, blacksquare, square, filled). Values are shown as means +/- SE. *P < 0.05.
###end p 52
###begin p 53
###xml 11 14 11 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ATP</sub>
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 175 176 175 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 188 189 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 445 446 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 231 235 <span type="species:ncbi:10116">rats</span>
Local VMH KATP channel blockade blunts the effect of systemic KCOs to amplify the glucose counterregulatory response to hypoglycemia. Plasma glucagon (A), plasma epinephrine (B), and GIR (C) during hyperinsulinemic hypoglycemia in rats pretreated with systemic NN414 and with VMH microinjection of glibenclamide (*, blacksquare, square, filled) or systemic NN414 and VMH microinjection of vehicle (o, square). Values are shown as means +/- SE. *P < 0.005 vs. control study.
###end p 53
###begin p 54
###xml 53 55 53 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 281 282 281 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 303 304 303 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 328 329 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 342 343 342 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 556 557 523 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 443 447 <span type="species:ncbi:10116">rats</span>
###xml 515 519 <span type="species:ncbi:10116">rats</span>
Systemic delivery of a SUR-1-selective KCO (0.6 mg kg-1 NN414) amplified the glucose counterregulatory response to acute hypoglycemia in nondiabetic rodents with defective counterregulation after exposure to three episodes of antecedent recurrent hypoglycemia (RH). Peak glucagon (A), peak epinephrine (B), peak norepinephrine (C), and GIRs (D) during subsequent hyperinsulinemic hypoglycemia are shown. square, Recurrent hypoglycemia control rats; blacksquare, square, filled, NN414-treated recurrent hypoglycemia rats. Values are shown as means +/- SE. *P < 0.005 vs. control study.
###end p 54
###begin p 55
###xml 53 55 53 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 205 206 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 227 228 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 252 253 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 266 267 266 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 430 431 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 146 150 <span type="species:ncbi:10116">rats</span>
###xml 152 154 <span type="species:ncbi:10116">BB</span>
###xml 326 328 <span type="species:ncbi:10116">BB</span>
###xml 337 341 <span type="species:ncbi:10116">rats</span>
###xml 386 388 <span type="species:ncbi:10116">BB</span>
###xml 389 393 <span type="species:ncbi:10116">rats</span>
Systemic delivery of a SUR-1-selective KCO (0.6 mg kg-1 NN414) amplified the glucose counterregulatory response to acute hypoglycemia in diabetic rats (BB) with defective counterregulation. Peak glucagon (A), peak epinephrine (B), peak norepinephrine (C), and GIRs (D) during subsequent hyperinsulinemic hypoglycemia. square, BB control rats; blacksquare, square, filled, NN414-treated BB rats. Values are shown as means +/- SE. *P < 0.005 vs. control study.
###end p 55
###begin p 56
Effect of different intravenous doses of the SUR-1-selective KCO, NN414, on glucose, insulin, and C-peptide under basal and hyperinsulinemic-hypoglycemic conditions
###end p 56
###begin p 57
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05 vs. control;
###end p 57
###begin p 58
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05 after injection vs. baseline.
###end p 58

